Pfizer Inc.: Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Bivalent booster elicited approximately 4-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine in individuals older than 55 years

Related Keywords

United States ,Canada ,United Kingdom ,Sylke Maas ,Biontech Covid ,Albert Bourla ,Ugur Sahin ,Fosun Pharma ,Centers For Disease ,Linkedin ,Genentech ,European Commission ,Drug Administration ,Exchange Commission ,Pfizer ,Youtube ,Pfizer Inc ,European Union ,European Medicines Agency ,Roche Group ,Chief Executive Officer ,Marketing Authorization Holder ,Emergency Use Authorization ,Coronavirus Disease ,Disease Control ,Vaccine Adverse Event Reporting System ,Prescribing Information ,Vaccination Providers ,Caregivers Fact Sheets ,Breakthroughs That Change Patient ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,New Technologies ,Private Securities Litigation Reform Act ,Quarterly Report ,Iontech ,Nnounce ,Pdated ,Linical ,Data ,Micron ,Adapted ,Bivalent ,Rooster ,Emonstrating ,Substantially ,Higher ,Immune ,Response ,Adults ,Ompared ,Original ,Covid ,Vaccine ,